MedPath

Studing the Effect of Dexmedetomidin in Controlling Agitation in Patients With Bipolar Disorder(RCT)

Phase 3
Recruiting
Conditions
agitation.
Registration Number
IRCT20230630058623N1
Lead Sponsor
Arak University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
104
Inclusion Criteria

All patients with bipolar disorder referred to Amirkabir Arak Hospital, who are in the treatment service of supervisors and consultants, and the treatment and medication regimen for their bipolar disorder is the same.
All bipolar patients who have signed an informed consent form to enter the study.
Patients in the age range of 18 to 45 years
Patients with BMI in the range of 20 to 30
Patients with bipolar disorder who do not have other psychiatric diseases at the same time.
No history of underlying heart, lung, kidney and liver diseases
No history of recent CVA or MI
Not receiving anticonvulsant drugs.
Absence of pregnancy and breastfeeding
Not allergic to dexmedetomidine
Patients who do not have very severe agitation

Exclusion Criteria

All patients who have severe agitation
All patients who have a severe allergy or reaction to the drug after injection and need cardiorespiratory support

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Agitation score. Timepoint: After drug injection in ECT recovery department. Method of measurement: Agitation scoring questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath